BioNTech SE Sponsored ADR $BNTX Shares Bought by TD Asset Management Inc

TD Asset Management Inc raised its position in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 1,417.6% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 173,795 shares of the company’s stock after buying an additional 162,343 shares during the period. TD Asset Management Inc’s holdings in BioNTech were worth $18,513,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Goodman Advisory Group LLC acquired a new position in BioNTech during the 1st quarter worth about $105,000. Vontobel Holding Ltd. increased its stake in BioNTech by 2.3% during the first quarter. Vontobel Holding Ltd. now owns 21,882 shares of the company’s stock worth $1,993,000 after purchasing an additional 497 shares during the period. OneDigital Investment Advisors LLC acquired a new stake in shares of BioNTech during the first quarter worth about $288,000. GF Fund Management CO. LTD. lifted its position in shares of BioNTech by 22.0% during the first quarter. GF Fund Management CO. LTD. now owns 2,514 shares of the company’s stock worth $229,000 after purchasing an additional 453 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in shares of BioNTech by 18,892.9% in the first quarter. Bank of New York Mellon Corp now owns 698,368 shares of the company’s stock valued at $63,593,000 after purchasing an additional 694,691 shares during the period. Hedge funds and other institutional investors own 15.52% of the company’s stock.

BioNTech Stock Performance

Shares of BNTX stock opened at $105.14 on Friday. The company has a market cap of $25.28 billion, a P/E ratio of -65.71 and a beta of 1.45. The firm has a fifty day moving average price of $103.76 and a 200 day moving average price of $103.88. The company has a current ratio of 8.61, a quick ratio of 8.48 and a debt-to-equity ratio of 0.01. BioNTech SE Sponsored ADR has a 12 month low of $81.20 and a 12 month high of $129.27.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings results on Monday, August 4th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.41) by ($0.19). BioNTech had a negative return on equity of 1.84% and a negative net margin of 12.20%.The business had revenue of $306.46 million for the quarter, compared to analysts’ expectations of $161.26 million. During the same period last year, the firm earned ($3.36) earnings per share. The firm’s quarterly revenue was up 102.6% on a year-over-year basis. BioNTech has set its FY 2025 guidance at EPS. Sell-side analysts predict that BioNTech SE Sponsored ADR will post -3.88 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on BNTX shares. Morgan Stanley cut their target price on shares of BioNTech from $133.00 to $131.00 and set an “overweight” rating on the stock in a research note on Friday, October 10th. HC Wainwright reaffirmed a “buy” rating and set a $136.00 price objective on shares of BioNTech in a research report on Monday, September 8th. JPMorgan Chase & Co. lifted their target price on BioNTech from $116.00 to $121.00 and gave the company a “neutral” rating in a report on Monday, September 22nd. Bank of America boosted their target price on BioNTech from $126.00 to $134.00 and gave the stock a “buy” rating in a research note on Tuesday, August 5th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of BioNTech in a research note on Tuesday. Ten research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, BioNTech currently has an average rating of “Moderate Buy” and an average target price of $134.32.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.